105183-11-7

Upstream product

• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 107-30-2 chloromethyl methyl ether 
• 6986-48-7 bis-1-chloroethyl ether 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 13057-17-5 bromethyl methyl ether 

Downstream Products

• 1020399-81-8 C₂₁H₂₀N₂O₉ 

Relevant academic research and scientific papers

Scalable Total Synthesis of (+)- And (-)-Codonopiloneolignanin A via Ti(IV)/NHC Cooperative Control Highly Enantioselective Dimerization of Multisubstituted Cinnamaldehyde

The first gram-scale asymmetric total synthesis of (+)- and (-)-codonopiloneolignanin A has been achieved from multisubstituted cinnamaldehyde in four steps with 37% overall yield. The synthetically challenging tricyclic [5, 3, 0, 03,8] decane skeleton was efficiently constructed via a highly enantioselective dimerization of multisubstituted cinnamaldehyde, followed by a sequence of cascade reactions including Prins cyclization, cation mediated cyclization, and deprotection. Furthermore, the scope of NHC-catalyzed/Ti(IV)-mediated synergistic control multisubstituted cinnamaldehyde dimerization was investigated. Significantly, the bioactivity of codonopiloneolignanin A and its enantiomer, particularly scarce in nature, was tested and showed good anticancer activity.

Epigenetic multiple ligands: Mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (Sirtuin) inhibitors

A number of new compounds bearing two ortho-bromo- and ortho,ortho- dibromophenol moieties linked through a saturated/unsaturated, linear/(poly)cyclic spacer (compounds 1-9) were prepared as simplified analogues of AMI-5 (eosin), a recently reported inhibitor of both protein arginine and histone lysine methyltransferases (PRMTs and HKMTs). Such compounds were tested against a panel of PRMTs (RmtA, PRMT1, and CARM1) and against human SET7 (a HKMT), using histone and nonhistone proteins as a substrate. They were also screened against HAT and SIRTs, because they are structurally related to some HAT and/or SIRT modulators. From the inhibitory data, some of tested compounds (1b, 1c, 4b, 4f, 4j, 4l, 7b, and 7f) were able to inhibit PRMTs, HKMT, HAT, and SIRTs with similar potency, thus behaving as multiple ligands for these epigenetic targets (epi-MLs). When tested on the human leukemia U937 cell line, the epi-MLs induced high apoptosis levels [i.e., 40.7% (4l) and 42.6% (7b)] and/or massive, dose-dependent cytodifferentiation [i.e., 95.2% (1c) and 96.1% (4j)], whereas the single-target inhibitors eosin, curcumin, and sirtinol were ineffective or showed a weak effect.

Phenoxyacetic acid compounds, method for production thereof, and pharmaceutical preparations containing same

A phenoxyacetic acid compound represented by the general formula I: STR1 wherein X is one member selected from the class consisting of hydrogen atom, halogen atoms, lower alkyl groups, trifluoromethyl group, alkoxy groups, hydroxy group, and cyano group,